Cargando…

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

BACKGROUND: Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar with similar efficacy and comparable safety and immunogenicity to reference adalimumab (ref-ADL) as confirmed by analytical, pharmacokinetic and confirmatory studies. ADMYRA, a phase III double-blind study, was cond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiland, Piotr, Jeka, Sławomir, Dokoupilová, Eva, Brandt-Jürgens, Jan, Miranda Limón, Juan Manuel, Cantalejo Moreira, Miguel, Cabello, Raul Veiga, Jauch-Lembach, Julia, Thakur, Anjali, Haliduola, Halimuniyazi, Brueckmann, Ines, Gaylis, Norman B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669771/ https://www.ncbi.nlm.nih.gov/pubmed/33119861 http://dx.doi.org/10.1007/s40259-020-00447-6

Ejemplares similares

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
por: Blauvelt, Andrew, et al.
Publicado: (2021)

In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.
por: Brunton, V. G., et al.
Publicado: (1993)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
por: Jaworski, Janusz, et al.
Publicado: (2019)

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Recent advances in ADL, CutLang and adl2tnm
por: Unel, Gokhan
Publicado: (2021)

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997)

Modulation of Multidrug Resistance by SDZ PSC 833 in Leukemic and Solid‐tumor‐bearing Mouse Models
por: Watanabe, Toru, et al.
Publicado: (1996)

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial
por: Suh, Chang-Hee, et al.
Publicado: (2019)

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
por: Colombo, T., et al.
Publicado: (1996)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2018)

Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64
por: Iwaszko, Milena, et al.
Publicado: (2018)

Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein
por: Kusunoki, Nobuya, et al.
Publicado: (1998)

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
por: Kay, Jonathan, et al.
Publicado: (2021)

Prediction for doubly charged Higgs using ADL
por: Ohrnberg, Ronja
Publicado: (2022)

FuncADL: Functional Analysis Description Language
por: Proffitt, Mason
Publicado: (2021)

EDUCATION AND PERCEIVED FUTURE NEED FOR ADL HELP
por: Finan, Julia
Publicado: (2022)

SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
por: Loor, F., et al.
Publicado: (1992)

Auxin-Inducible Depletion of the Essentialome Suggests Inhibition of TORC1 by Auxins and Inhibition of Vrg4 by SDZ 90-215, a Natural Antifungal Cyclopeptide
por: Snyder, Nathan A., et al.
Publicado: (2019)

Predictors of ADL Disability in Culturally Diverse Older Adults
por: WINCHESTER, FERNANDA, et al.
Publicado: (2009)

Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
por: de Meel, R. H. P., et al.
Publicado: (2018)

Development and content validation of an ADL questionnaire for hemiplegic shoulder
por: Chatterjee, Subhasish, et al.
Publicado: (2023)

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial
por: Shim, Seung Cheol, et al.
Publicado: (2019)

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial
por: Park, Won, et al.
Publicado: (2018)

Validity and reliability of the Arabic version of Activities of Daily Living (ADL)
por: Nasser, Ramzi, et al.
Publicado: (2009)

The Onset of ADL Difficulties and Changes in Health-Related Quality of Life
por: Lyu, Wei, et al.
Publicado: (2017)

Depressive symptoms in individuals with family members requiring ADL assistance
por: Kwon, Junhyun, et al.
Publicado: (2019)

An Evaluation of Graphical Formats for the Summary of Activities of Daily Living (ADLs)
por: Byrne, Caroline A., et al.
Publicado: (2020)

Rank Pooling Approach for Wearable Sensor-Based ADLs Recognition
por: Nisar, Muhammad Adeel, et al.
Publicado: (2020)

Determinants of ADL and IADL disability in older adults in southeastern Poland
por: Ćwirlej-Sozańska, Agnieszka, et al.
Publicado: (2019)

Inertial Data-Based AI Approaches for ADL and Fall Recognition
por: Martins, Luís M., et al.
Publicado: (2022)

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2022)

Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis
por: Iwaszko, Milena, et al.
Publicado: (2020)

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis
por: Park, Won, et al.
Publicado: (2017)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

ADL/CutLang developments towards large scale (re)interpretation
por: Unel, Gokhan
Publicado: (2022)

Correction to: Depressive symptoms in individuals with family members requiring ADL assistance
por: Kwon, Junhyun, et al.
Publicado: (2019)

On the characteristics of reporting ADL limitations and formal LTC usage across Europe
por: Fuino, Michel, et al.
Publicado: (2020)

Multivariate analysis of independent determinants of ADL/IADL and quality of life in the elderly
por: Beltz, Sebastian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gbo1js2ddvmnc4nmt6js02mboc